Auron Therapeutics
Auron Therapeutics, Inc.
Delivering next-generation cancer therapies targeting cell state
aurontx.com · Wellesley, MA
Funding event
The round itself, as filedInferred stageSeries A
Sold of offered$7.1M of $12.0M
Filed2026-08-13
Days since filing52
- Exemption claimed
- Rule 506(b)
- First-ever Form D
- No
- Date of first sale
- 2026-08-10
Investors
No investors named: Form D does not list them
Officers on the filing
Names and roles as filed; addresses are never stored- Katharine YenExecutive Officer · Director
- Alexandra CantleyDirector
- Briggs Duncan MorrisonDirector
- Anna FrenchDirector
- Pini OrbachDirector
- Serge MesserlianDirector
- Victoria RichonDirector
Health flags
Three flags, each with the raw inputs behind it · as of 2026-10-03UndersubscribedNot flagged59.3% sold1.8 months since first sale
Prior raiseNot flaggedPrior raise not known—
AmendedNot flaggedNo amendmentNo D/A on file
Open roles
On the employer's own careers page · checked 2026-09-241
Pre-posting windowNot enough dataShown once this sector and stage have 20 observed lags from filing to first posting.
- Medical Director/Senior Medical DirectorSEP 25open 9 days
Also raised in Health & bio
Same sector, 28 days to 2026-10-04Altay TherapeuticsSeries A · $15.7M of $45.1M · San Carlos, CAQuietCarebilitySeries A · $8.8M of $8.8M · Richardson, TXQuiet
75 rounds in Health & bio in the 28 days to 2026-10-03, against 71 in the 28 days before.